Mode
Text Size
Log in / Sign up
Phase 1 Completed N=52 Randomized Single-blind Treatment

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Healthy
Source: ClinicalTrials.gov NCT02232087 ↗
Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcomePrimary: Relative Potency Max Heart Rate — 0.8619 unitless — p=>0.10

Summary

The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.

Outcome Measures

OutcomeResultp-value
PRIMARY
Relative Potency Max Heart Rate
0.8619 >0.10
PRIMARY
Relative Potency QTcB Interval
1.0760 >0.10
SECONDARY
Max Heart Rate
65.1; 65.5; 68.9; 69.9; 75.3; 76.8 0.55
SECONDARY
Plasma Potassium Level
3.82; 3.78; 3.76; 3.75; 3.63; 3.61 0.26
SECONDARY
Max Plasma Glucose Level
5.31; 5.31; 5.53; 5.62; 5.88; 5.98 0.93
SECONDARY
Max QTcB
422.3; 422.1; 430.0; 430.2; 441.0; 444.0 0.71

Eligibility Criteria

Inclusion Criteria

  • Healthy Volunteer
  • Willing and able to give informed consent
  • Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
  • Male and female subjects aged 18 to 55 years (inclusive)
  • Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration

Exclusion Criteria

  • Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders
  • Any presence or history of a clinically significant allergy including any adverse reaction to study drug
  • History of drug or alcohol abuse within the past 2 years
  • Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)
  • Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
  • Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
  • If female, nursing, lactating or pregnant
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Surgery scheduled during the study or within 3 weeks after last dose
  • History of familial long QT syndrome or history of sudden death in family members aged < 30 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02232087). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search